Research Article
BibTex RIS Cite

The Evaluation Of Metabolic Syndrome Frequency And Its Components In Newly Diagnosed Type-2 Diabetic Patients

Year 2012, Volume: 12 Issue: 4, 174 - 177, 01.04.2012

Muhammet Oktay Gülseren Oktay Yusuf Ertekin Cemil Sönmez Feruze Sönmez

Abstract

Purpose: We planned this study in order to identify the
relationship between metabolic syndrome and its components and the frequency of it in untreated type- 2 DM
patients and in patients with new diagnosis type 2- DM.
Methods: In the study, 220 diabetic patients were questioned on weight, height, waist circumference, body mass
index, fasting blood glucose, blood pressure, HbA1c, total
cholesterol, triglycerides, LDL, HDL data, in addition to the
components of metabolic syndrome in first-degree relatives.
Results: In our study on new diagnosed type-2 diabetic
patients, the frequency of metabolic syndrome (MS) was
found 70.5%,according to National Cholesterol Education
Program (NCEP), and 80% according to the International
Diabetes Federation (IDF) . The rates of MS by gender in
women and men was 84.8% and 75.6%, respectively. Obesity was found as the most frequent MS component in all
the first-degree relatives of the patients; parents, sisters,
brothers and children .
Discussion: Waist circumference was found to be the best
reflecting criteria of insulin resistance. According to the
NCEP criteria, no significant difference was found in fasting blood glucose levels in MS and non MS patients. The
reason for this was thought to be the fact that NCEP kept
fasting blood glucose threshold value low, in order to reduce the long-term risks.
The entity that obesity was found in all the first-degree
relatives of the diabetic patients aroused the suspicion
that obesity disease may be transferred with the same
genes with diabetes and insulin resistance.

Keywords

Diabetes insulin resistance metabolic syndrome obesity

References

  • 1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229-34.
  • 2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-942
  • 3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24:683-689.
  • 4. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18-25.
  • 5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421.
  • 6. Alberti KG, Zimmet P, Shaw J ; International Diabetes Federation (IDF) Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62.
  • 7. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr. 2007 Apr;61(4):548-53.
  • 8. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III). National Cholesterol Education Program (NCEP). NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214

Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı ve Bileşenlerinin Değerlendirilmesi

Year 2012, Volume: 12 Issue: 4, 174 - 177, 01.04.2012

Muhammet Oktay Gülseren Oktay Yusuf Ertekin Cemil Sönmez Feruze Sönmez

Abstract

Amaç:

Çalışmayı yeni tespit edilen veya hiç tedavi almamış tip 2 diyabetik hastalarda metabolik sendrom ve bileşenlerinin sıklığını ve ilişkisini belirleyebilmek amacıyla planladık.

Metod:

Çalışmaya alınan 220 diyabetik hastanın kilo, boy, bel çevresi, vücut kitle indeksi, açlık kan şekeri, tansiyon, HbA1c, total kolesterol, trigliserid, LDL, HDL verilerine ek olarak birinci derece akrabalarında, metabolik sendrom bileşenleri sorgulandı.

Sonuç:

Yeni tespit edilen tip 2 diyabetik hastalarla yaptığımız çalışmamızda, Metabolik Sendrom(MS) sıklığını Ulusal Kolesterol Eğitim Programı(NCEP)’na göre %70,5, Uluslararası Diyabet Federasyonu (IDF)’na göre %80 olarak tespitedildi. Cinsiyete göre kadın ve erkekte MS olma oranları sırayla %84,8 ve %75,6 idi. Hastaların birinci derece akrabaları olan ebeveyn, kardeş ve çocukların tümünde MS bileşeni olarak obezite birinci sırada yer aldı.

Tartışma:

İnsülin direncini en iyi yansıtan kriterin yine bel çevresi olduğu görüldü. NCEP’in kriterlerine göre MS olan ile olmayan hastaların AKŞ değerlerinde anlamlı bir farklılık saptanmamasının sebebi olarak NCEP’nin uzun dönemde riski azaltmak için AKŞ’nin eşik değerini düşük tuttuğu düşünüldü. Diyabetli hastaların anne, baba, kardeş ve çocuklarında obezitenin birinci sırada ve sıklıkla yer alması, obezitenin diyabet ve insülin direnci ile ortak genlerden aktarılabilecek bir hastalık olabileceği şüphesini uyandırdı.

Keywords

Diyabet insülin direnci metabolik sendrom obezite

References

  • 1. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 Jul 23;339(4):229-34.
  • 2. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-942
  • 3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24:683-689.
  • 4. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18-25.
  • 5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421.
  • 6. Alberti KG, Zimmet P, Shaw J ; International Diabetes Federation (IDF) Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet. 2005 Sep 24-30;366(9491):1059-62.
  • 7. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr. 2007 Apr;61(4):548-53.
  • 8. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III). National Cholesterol Education Program (NCEP). NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-1214
There are 8 citations in total.

Details

Primary Language Turkish
Journal Section Research Articles
Authors

Muhammet Oktay This is me

Gülseren Oktay This is me

Yusuf Ertekin

Cemil Sönmez This is me

Feruze Sönmez This is me

Publication Date April 1, 2012
Published in Issue Year 2012 Volume: 12 Issue: 4

Cite

APA Oktay, M., Oktay, G., Ertekin, Y., Sönmez, C., et al. (2012). Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı ve Bileşenlerinin Değerlendirilmesi. Ankara Medical Journal, 12(4), 174-177.
AMA Oktay M, Oktay G, Ertekin Y, Sönmez C, Sönmez F. Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı ve Bileşenlerinin Değerlendirilmesi. Ankara Med J. April 2012;12(4):174-177.
Chicago Oktay, Muhammet, Gülseren Oktay, Yusuf Ertekin, Cemil Sönmez, and Feruze Sönmez. “Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı Ve Bileşenlerinin Değerlendirilmesi”. Ankara Medical Journal 12, no. 4 (April 2012): 174-77.
EndNote Oktay M, Oktay G, Ertekin Y, Sönmez C, Sönmez F (April 1, 2012) Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı ve Bileşenlerinin Değerlendirilmesi. Ankara Medical Journal 12 4 174–177.
IEEE M. Oktay, G. Oktay, Y. Ertekin, C. Sönmez, and F. Sönmez, “Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı ve Bileşenlerinin Değerlendirilmesi”, Ankara Med J, vol. 12, no. 4, pp. 174–177, 2012.
ISNAD Oktay, Muhammet et al. “Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı Ve Bileşenlerinin Değerlendirilmesi”. Ankara Medical Journal 12/4 (April 2012), 174-177.
JAMA Oktay M, Oktay G, Ertekin Y, Sönmez C, Sönmez F. Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı ve Bileşenlerinin Değerlendirilmesi. Ankara Med J. 2012;12:174–177.
MLA Oktay, Muhammet et al. “Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı Ve Bileşenlerinin Değerlendirilmesi”. Ankara Medical Journal, vol. 12, no. 4, 2012, pp. 174-7.
Vancouver Oktay M, Oktay G, Ertekin Y, Sönmez C, Sönmez F. Yeni Tespit Tip 2 Diyabetik Hastalarda Metabolik Sendrom Sıklığı ve Bileşenlerinin Değerlendirilmesi. Ankara Med J. 2012;12(4):174-7.
 Download Cover Image